GL1X · GenesisL1 explorer

MolNFT v1 · #120296 · protein

Plasmodium vivax shmt bound with plp-glycine and GS654

5GVP · Serine hydroxymethyltransferase, putative: “Plasmodium vivax shmt bound with plp-glycine and GS654”. X-ray diffraction, 3 ligands (PLG, GCF, CL), 13 pockets (best druggability 0.75). MolNFT v1 #120296 on GenesisL1: 3D structure…

PDB
5GVP
Type
protein
Length
1,326 residues
Chains
3
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Serine hydroxymethyltransferase, putative
UniProt
A5K8L9
Ligands
PLG, GCF, CL
Pockets
13 · best druggability 0.75

Structure

x-ray diffraction · 1 distinct chain · 49% helix, 13% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, B, CSerine hydroxymethyltransferase, putativeprotein44249% helix, 13% strandA5K8L9

Ligands and binding sites

  • PLG · N-glycine-[3-hydroxy-2-methyl-5-phosphonooxymethyl-pyridin-4-yl-methane] · ligand · 3 copies · chains A, B, C
  • GCF · 3-[3-[3-[(4~{S})-6-azanyl-5-cyano-3-methyl-4-propan-2-yl-2~{H}-pyrano[2,3-c]pyrazol-4-yl]-5-(trifluoromethyl)phenyl]phenyl]propanoic acid · ligand · 3 copies · chains A, B, C
  • CL · Chloride ion · ion · 2 copies · chains A, B, C

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

13 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
14150.750.8557GCF, PLG
23150.750.8744PLG, GCF
39170.730.7768empty
4740.720.9620empty
51660.460.7631PLG, GCF

Interfaces

2 interfaces between chains.

  • A–B · 4749 Ų buried · 63 hydrogen bonds · protein-protein
  • B–C · 395 Ų buried · 6 hydrogen bonds · protein-protein

Compared structures

  • 5GVP · Plasmodium vivax SHMT bound with PLP-glycine and GS654 · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.